Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including lenacapavir—HIV’s ability to evolve resistance to the breakthrough antiviral.

A new antiretroviral target has been identified that suppresses HIV-1 replication and selectively kills HIV-1-infected cells. HIV-1 is the most common type of HIV. When HIV-1 leaves infected cells, ...

The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain. While symptoms can now be better managed with lifelong treatment, there is ...

HIV is a human-specific pathogen that does not cause disease in other species, although it can replicate in chimpanzees. HIV cannot infect mice, rats, rabbits, or macaques. Previous HIV mouse models ...

Since HIV’s discovery in the 1980s, scientists have come a long way in understanding the different steps required for its assembly and maturation. Researchers knew, for instance, that HIV wraps its ...

Previous attempts at making HIV vaccines elicit an important antibody response have often required long experiments in large animal models. Now, researchers say they've been able to produce the prized ...